Skip to main content

and
  1. No Access

    Article

    CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute myeloid leukemia

    M C Guastadisegni, A Lonoce, L Impera, F Di Terlizzi, G Fugazza, S Aliano in Leukemia (2010)

  2. No Access

    Article

    Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

    The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20–30% blasts tr...

    R Itzykson, O Kosmider, T Cluzeau, V Mansat-De Mas, F Dreyfus, O Beyne-Rauzy in Leukemia (2011)

  3. No Access

    Article

    Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

    Although next-generation sequencing has allowed for the detection of somatic mutations in myelodysplastic syndromes (MDS), the clinical relevance of variant allele frequency (VAF) for the majority of mutations...

    D A Sallman, R Komrokji, C Vaupel, T Cluzeau, S M Geyer, K L McGraw, N H Al Ali in Leukemia (2016)

  4. Article

    Open Access

    Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

    A. S. Kubasch, P. Peterlin, T. Cluzeau, K. S. Götze, K. Sockel, R. Teipel in Leukemia (2023)